OBJECTIVE: To provide a comprehensive review of the discovery and development of selective thyroid hormone receptor agonists and provide a discussion of their use in hyperlipidemia, obesity, and type 2 diabetes mellitus. METHODS: Preclinical and clinical English language literature from 1930 to present was reviewed and thematically summarized. RESULTS: Human trials have shown that thyroid hormone receptor β (TRβ) agonists effectively lower low-density lipoprotein, triglycerides, apolipoprotein B, and lipoprotein(a) levels. In preclinical studies, TRβ agonists enhance reverse cholesterol transport and decrease atherosclerosis in selected models. While animal data suggest these drugs may have additional utility to modulate weight and improve glucose homeostasis, human studies have not shown similar results. CONCLUSION: TRβ agonists are a novel therapeutic class for lipid management. Their mechanism of action for lipid lowering is distinct from statin drugs, suggesting a strong possibility for synergistic effects with combined therapy. The long-term effects of these drugs on cardiovascular outcomes, however, are unknown. Recently, the development of the most promising agent in this class, eprotirome, was halted over toxicology concerns following long-term canine studies. Consequently, the future of contemporary TRβ agonists is unclear. The creation of a next generation of TRβ agonists that provide additional tissue specific effects or bind TRβ with even higher selectivity may lead to improved safety and efficacy and allow for their application to other metabolic disorders like obesity and type 2 diabetes mellitus.
OBJECTIVE: To provide a comprehensive review of the discovery and development of selective thyroid hormone receptor agonists and provide a discussion of their use in hyperlipidemia, obesity, and type 2 diabetes mellitus. METHODS: Preclinical and clinical English language literature from 1930 to present was reviewed and thematically summarized. RESULTS:Human trials have shown that thyroid hormone receptor β (TRβ) agonists effectively lower low-density lipoprotein, triglycerides, apolipoprotein B, and lipoprotein(a) levels. In preclinical studies, TRβ agonists enhance reverse cholesterol transport and decrease atherosclerosis in selected models. While animal data suggest these drugs may have additional utility to modulate weight and improve glucose homeostasis, human studies have not shown similar results. CONCLUSION: TRβ agonists are a novel therapeutic class for lipid management. Their mechanism of action for lipid lowering is distinct from statin drugs, suggesting a strong possibility for synergistic effects with combined therapy. The long-term effects of these drugs on cardiovascular outcomes, however, are unknown. Recently, the development of the most promising agent in this class, eprotirome, was halted over toxicology concerns following long-term canine studies. Consequently, the future of contemporary TRβ agonists is unclear. The creation of a next generation of TRβ agonists that provide additional tissue specific effects or bind TRβ with even higher selectivity may lead to improved safety and efficacy and allow for their application to other metabolic disorders like obesity and type 2 diabetes mellitus.
Authors: J Wouter Jukema; Cheng-Wen Chiang; Jean Ferrières; Raul D Santos; Juan Verdejo; David D Waters; Michael Messig; Lisa Tarasenko Journal: Curr Med Res Opin Date: 2010-09-29 Impact factor: 2.580
Authors: S U Trost; E Swanson; B Gloss; D B Wang-Iverson; H Zhang; T Volodarsky; G J Grover; J D Baxter; G Chiellini; T S Scanlan; W H Dillmann Journal: Endocrinology Date: 2000-09 Impact factor: 4.736
Authors: Galina Bryzgalova; Suad Effendic; Akhtar Khan; Stefan Rehnmark; Peter Barbounis; Jamie Boulet; Gao Dong; Rajni Singh; Sue Shapses; Johan Malm; Paul Webb; John D Baxter; Gary J Grover Journal: J Steroid Biochem Mol Biol Date: 2008-06-22 Impact factor: 4.292
Authors: Ivan Tancevski; Egon Demetz; Philipp Eller; Kristina Duwensee; Julia Hoefer; Christiane Heim; Ursula Stanzl; Andreas Wehinger; Kristina Auer; Regina Karer; Julia Huber; Wilfried Schgoer; Miranda Van Eck; Jonathan Vanhoutte; Catherine Fievet; Frans Stellaard; Mats Rudling; Josef R Patsch; Andreas Ritsch Journal: PLoS One Date: 2010-01-15 Impact factor: 3.240
Authors: Livia López-Noriega; Nadia Cobo-Vuilleumier; Álvaro Jesús Narbona-Pérez; Juan Luis Araujo-Garrido; Petra Isabel Lorenzo; José Manuel Mellado-Gil; José Carlos Moreno; Benoit R Gauthier; Alejandro Martín-Montalvo Journal: Br J Pharmacol Date: 2017-09-20 Impact factor: 8.739
Authors: Mason T Breitzig; Matthew D Alleyn; Richard F Lockey; Narasaiah Kolliputi Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-09-27 Impact factor: 5.464